IPO7 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, curcumin increases miR-22 that directly targets IPO7 in chronic myelogenous leukemia cells [102], indicating that curcumin modulates HIF-1α activity via the miR-22/IPO7 axis (Figure 2 and Table 2).